Genmab A-S News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.12.24	Genmab to Hold 2024 R&D Update and ASH Data Review Meeting (GlobeNewswire)
09.12.24	Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (GlobeNewswire)
08.12.24	Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukem (GlobeNewswire)
08.12.24	Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) (GlobeNewswire)
03.12.24	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
03.12.24	Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons (GlobeNewswire)
25.11.24	Genmab to Present at Citi’s Global Healthcare Conference (GlobeNewswire)
21.11.24	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
08.11.24	A Closer Look at 10 Analyst Recommendations For Genmab (Benzinga)
06.11.24	Genmab Announces Financial Results for the First Nine Months of 2024 (GlobeNewswire)
05.11.24	Genmab to Present at Jefferies London Healthcare Conference (GlobeNewswire)
05.11.24	Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
05.11.24	Ausblick: Genmab A-S präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
22.10.24	Erste Schätzungen: Genmab A-S legt Zahlen zum jüngsten Quartal vor (finanzen.net)
16.10.24	12 Analysts Have This To Say About Genmab (Benzinga)
15.10.24	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024 (GlobeNewswire)
04.10.24	Major Shareholder Announcement (GlobeNewswire)
26.09.24	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
15.09.24	Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial (GlobeNewswire)
10.09.24	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
09.09.24	Expert Ratings For Genmab (Benzinga)
26.08.24	Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
20.08.24	Decoding 10 Analyst Evaluations For Genmab (Benzinga)
19.08.24	TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma (GlobeNewswire)
16.08.24	Genmab Announces Changes to its Executive Committee (GlobeNewswire)
13.08.24	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
13.08.24	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
08.08.24	Genmab Announces Financial Results for the First Half of 2024 (GlobeNewswire)
08.08.24	Genmab Updates 2024 Financial Guidance (GlobeNewswire)
07.08.24	Ausblick: Genmab A-S präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
05.08.24	Genmab Takes Full Control of Acasunlimab Development Program (GlobeNewswire)
01.08.24	What 8 Analyst Ratings Have To Say About Genmab (Benzinga)
24.07.24	Erste Schätzungen: Genmab A-S stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
17.07.24	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024 (GlobeNewswire)
17.07.24	Erste Schätzungen: Genmab A-S gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
15.07.24	What 8 Analyst Ratings Have To Say About Genmab (Benzinga)
28.06.24	Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma (GlobeNewswire)
27.06.24	Completion of Share Buy-back Program (GlobeNewswire)
27.06.24	EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) (GlobeNewswire)
24.06.24	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
20.06.24	10 Analysts Assess Genmab: What You Need To Know (Benzinga)
18.06.24	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
17.06.24	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
12.06.24	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Genmab A-S

Aktien Top/Flop

Genmab A-S Peer Group Nachrichten

Meistgelesene Nachrichten